^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
02/16/2021
Excerpt:
PD-L1 expression positive (≥50%)…Adenocarcinoma, large cell, NSCLC NOS…other recommended…Carboplatin + paclitaxel + bevacizumab + atezolizumab
Source:
Title:
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients Studio randomizzato di fase II di confronto tra atezolizumab versus atezolizumab più bevacizumab come trattamento di prima linea in pazienti con sovraespressione di PD-L1 con carcinoma polmonare non a piccole cellule avanzato
Excerpt:
...1) Histologically confirmed diagnosis of stage IV non-squamous NSCLC with no evidence of EGFR sensitizing mutations or ALK or ROS1 rearrangements.2) Availability of tumor tissue.3) 3) Evidence of high levels of PD-L1 expression evaluated with immunohistochemistry (=50% by 22C3 or SP263 or TC/IC 3 scoring by SP 142) .4) No previous chemotherapy. ...
Trial ID:
Source:
Title:
LBA55 - WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression
Published date:
09/19/2020
Excerpt:
...As of 31 March 2020, none and 25 of the 39 patients were judged as CR and PR, indicating that ORR was 64.1% (95%CI: 47.2-78.8). One year PFS rate was 54.9%....This positive result supports Atez with Bev as a potential treatment option for non-Sq NSCLC with high PD-L1 expression.
